Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations

Area of Science:

• Medical Oncology
• Immunotherapy
• Thoracic Cancers

Background:

• Non-small cell lung cancer (NSCLC) treatment landscape is evolving, particularly for first-line management.
• Immune checkpoint inhibitors (ICI) have revolutionized NSCLC therapy, but challenges remain regarding patient selection, resistance, and long-term management.
• Understanding treatment resistance and identifying predictive biomarkers are crucial for optimizing patient care.

Purpose of the Study:

• To provide a comprehensive overview of current first-line treatment strategies for NSCLC.
• To address key clinical decision-making questions regarding ICI therapy in NSCLC.
• To review emerging therapeutic modalities and future directions in NSCLC treatment.

Main Methods:

• Literature review of current treatment approaches for first-line NSCLC.
• Analysis of clinical decision-making queries related to ICI therapy.
• Evaluation of evidence for various treatment strategies, including chemotherapy, ICI, and novel agents.

Main Results:

• Optimal strategies for PD-L1-high NSCLC patients are discussed, alongside predictive factors for ICI response.
• The benefits of dual checkpoint blockade and safe discontinuation strategies for long-term responders are examined.
• Docetaxel-based regimens remain a backbone for post-ICI treatment, though evidence is limited; novel agents like antibody-drug conjugates show promise.

Conclusions:

• Effective management of NSCLC requires careful consideration of patient and tumor characteristics to optimize ICI therapy.
• Addressing primary and acquired resistance to ICI is critical, necessitating further research into combination strategies and novel agents.
• Emerging chemotherapy-free approaches and antibody-drug conjugates represent promising future directions for NSCLC treatment.